Only Takada et al. used three different PD-L1 antibodies (28.8, SP142 and E1L3N), of which two are FDA-approved, in a study that immunohistochemically analysed PD-L1 expression in surgically-resected SCLC [28,29]. This evidence concerns the gene CD274 and small cell lung carcinoma.